Atrin Pharmaceuticals 

Atrin Pharmaceuticals is a private biopharmaceutical company pioneering the discovery & development of proprietary molecules targeting DNA Damage and Response (DDR) pathways to treat a broad spectrum of cancers associated with synthetic lethality and the deregulated DNA Damage Response.

Atrin’s scientific founders were the first to discover the key role of the Ataxia Telangiectasia and Rad3-related (ATR) pathway in treating cancers.
The emerging role of DDR treatments in cancer is expected to represent a cornerstone in novel targeted monotherapy and combination anticancer therapies.  Atrin’s lead ATR molecules are projected to become best-in-class DDR inhibitors.
Atrin’s lead product is ATRN-119, a novel, potentially best-in-class small molecule ATR inhibitor. Atrin plans to initiate a first-in-human trial for ATRN-119 in early 2020.  

Copyright © 2019 Atrin Pharmaceuticals

Tel: 267-370-5219 | E-mail: info@atrinpharma.com